NASDAQ:VNDA

Vanda Pharmaceuticals (VNDA) Stock Forecast, Price & News

$6.06

+0.16 (+2.71%)

(As of 06/2/2023 ET)

Compare

Today's Range: $5.90
▼
$6.08
50-Day Range: $5.90
▼
$6.95
52-Week Range: $5.75
▼
$11.90

Volume: 658,681 shs
Average Volume: 517,848 shs
Market Capitalization: $348.09 million

P/E Ratio: 20.90
Dividend Yield: N/A
Price Target: N/A

Vanda Pharmaceuticals MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Bearish
5.19% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.77
Upright™ Environmental Score
News Sentiment: 0.37
Based on 5 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Decreasing
From ($0.44) to ($0.95) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.79 out of 5 stars

Medical Sector

729th out of 983 stocks

Pharmaceutical Preparations Industry

366th out of 486 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Vanda Pharmaceuticals.

1.0

Short Interest

Percentage of Shares Shorted
5.19% of the float of Vanda Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Vanda Pharmaceuticals has a short interest ratio ("days to cover") of 5.
Change versus previous month
Short interest in Vanda Pharmaceuticals has recently increased by 1.78%, indicating that investor sentiment is decreasing.

0.0

Dividend Strength

Dividend Yield
Vanda Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Vanda Pharmaceuticals does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Vanda Pharmaceuticals has received a 61.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Tasimelteon", "Antipsychotics", and "Clinical research services for psychotic disorders" products. See details.
Environmental Sustainability
The Environmental Impact score for Vanda Pharmaceuticals is -1.77.

1.9

News and Social Media Coverage

News Sentiment
Vanda Pharmaceuticals has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Vanda Pharmaceuticals this week, compared to 1 article on an average week.
Search Interest
Only 2 people have searched for VNDA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Vanda Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Vanda Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 7.00% of the stock of Vanda Pharmaceuticals is held by insiders.
Percentage Held by Institutions
97.22% of the stock of Vanda Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Vanda Pharmaceuticals are expected to decrease in the coming year, from ($0.44) to ($0.95) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Vanda Pharmaceuticals is 20.90, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 133.95.
Price to Earnings Ratio vs. Sector
The P/E ratio of Vanda Pharmaceuticals is 20.90, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.17.
Price to Book Value per Share Ratio
Vanda Pharmaceuticals has a P/B Ratio of 0.65. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Vanda Pharmaceuticals (NASDAQ:VNDA) Stock

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Receive VNDA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vanda Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

VNDA Stock News Headlines

June 4, 2023 | americanbankingnews.com

StockNews.com Lowers Vanda Pharmaceuticals (NASDAQ:VNDA) to Buy

June 2, 2023 | msn.com

Vanda gains on FDA orphan drug designation for nerve disorder candidate

June 4, 2023 | Behind the Markets (Ad)

How A.I. Could Make Most 21st Century Diseases EXTINCT

On December 22, 2022, AI discovered a new treatment for multiple myeloma... in just 4 months... On March 19, 2023, AI discovered a new drug for liver cancer... in only 30 days... There's one small-cap at the center of it all. Bill Gates owns 7 million shares... Billionaire hedge-fund manager Steve Cohen owns 1.4 million shares...

June 1, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Announces Orphan Drug Designation Granted for VCA-894A, a Novel Antisense Oligonucleotide Candidate for the Treatment of Charcot-Marie-Tooth Disease, Type 2S

June 1, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Announces Presentations at SLEEP 2023

May 30, 2023 | bizjournals.com

Vanda Pharmaceuticals eyeing ‘path forward’ for motion sickness treatment

May 25, 2023 | finance.yahoo.com

A Sea Change in Motion Sickness Therapy: Vanda Pharmaceuticals' Tradipitant Shows Promising Data in Real-world Test

May 25, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Reports Results from a Phase III study of Tradipitant in Motion Sickness

June 4, 2023 | Behind the Markets (Ad)

How A.I. Could Make Most 21st Century Diseases EXTINCT

May 24, 2023 | entrepreneur.com

4 Best Biotech Stocks According to POWR Ratings

May 20, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Vanda Pharmaceuticals (NASDAQ:VNDA)

May 10, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Responds to Ruling in HETLIOZ® ANDA Appeal

May 4, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Announces Presentations at DDW 2023

May 4, 2023 | finance.yahoo.com

Q1 2023 Vanda Pharmaceuticals Inc Earnings Call

May 3, 2023 | reuters.com

Vanda Pharmaceuticals sues US over drug-trade secrets

May 3, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Reports First Quarter 2023 Financial Results

May 2, 2023 | finance.yahoo.com

Vanda Pharmaceuticals sues U.S. government over drug trade secrets

May 2, 2023 | finance.yahoo.com

Vanda Pharmaceuticals Sues Federal Government for Misappropriation of Trade Secrets and Confidential Information

April 27, 2023 | finance.yahoo.com

Vanda Pharmaceuticals to Announce First Quarter 2023 Financial Results on May 3, 2023

April 23, 2023 | thestreet.com

Novartis to Market Vanda's Fanapt Drug

April 12, 2023 | uk.finance.yahoo.com

Vanda Pharmaceuticals Inc. (VNDA)

April 4, 2023 | finance.yahoo.com

Calculating The Fair Value Of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

March 30, 2023 | bizjournals.com

Vanda Pharmaceuticals wins lawsuit against FDA

March 28, 2023 | finance.yahoo.com

Vanda Prevails in Jet Lag Litigation Against the FDA

March 17, 2023 | prnewswire.com

Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors

February 26, 2023 | benzinga.com

Vanda Pharma Stock (NASDAQ:VNDA), Quotes and News Summary

February 10, 2023 | msn.com

Vanda Pharmaceuticals's Return On Capital Employed Insights

See More Headlines

VNDA Price History

30 days | 90 days | 365 days | Advanced Chart

VNDA Company Calendar

Last Earnings: 11/03/2021
Today: 6/03/2023
Next Earnings (Estimated): 8/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:VNDA
CUSIP: 92165910
CIK: 1347178
Web: www.vandapharma.com
Phone: (202) 734-3400
Fax: 202-296-1450
Employees: 278
Year Founded: 2002

Profitability

EPS (Most Recent Fiscal Year): $0.29
Trailing P/E Ratio: 20.90
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $6.28 million
Net Margins: 6.22%
Pretax Margin: 9.50%
Return on Equity: 3.06%
Return on Assets: 2.54%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 5.69
Quick Ratio: 5.68

Sales & Book Value

Annual Sales: $254.38 million
Price / Sales: 1.37
Cash Flow: $0.11 per share
Price / Cash Flow: 55.23
Book Value: $9.33 per share
Price / Book: 0.65

Miscellaneous

Outstanding Shares: 57,440,000
Free Float: 53,423,000
Market Cap: $348.09 million
Optionable: Optionable
Beta: 0.68

Social Links

Key Executives

Mihael Hristos Polymeropoulos
Chairman, President & Chief Executive Officer

Kevin Moran
Chief Financial Officer, Treasurer & SVP

Tim Williams
Secretary, Senior VP & General Counsel

Kim Wijkstrom
Senior Vice President & Chief Marketing Officer

Gunther Birznieks
Senior Vice President-Business Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

VNDA Stock - Frequently Asked Questions

How have VNDA shares performed in 2023?: Vanda Pharmaceuticals' stock was trading at $7.39 at the beginning of the year. Since then, VNDA stock has decreased by 18.0% and is now trading at $6.06.
View the best growth stocks for 2023 here.
When is Vanda Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 2nd 2023.
View our VNDA earnings forecast.
How were Vanda Pharmaceuticals' earnings last quarter?: Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) issued its earnings results on Wednesday, November, 3rd. The biopharmaceutical company reported $0.14 EPS for the quarter, missing analysts' consensus estimates of $0.20 by $0.06. The biopharmaceutical company earned $70.10 million during the quarter, compared to analyst estimates of $73.50 million. Vanda Pharmaceuticals had a trailing twelve-month return on equity of 3.06% and a net margin of 6.22%. During the same period in the prior year, the business posted $0.11 earnings per share.
What ETFs hold Vanda Pharmaceuticals' stock?: ETFs with the largest weight of Vanda Pharmaceuticals (NASDAQ:VNDA) stock in their portfolio include Virtus LifeSci Biotech Products ETF (BBP), Horizon Kinetics Medical ETF (MEDX), iShares Neuroscience and Healthcare ETF (IBRN), Invesco Nasdaq Future Gen 200 ETF (QQQS), Invesco S&P SmallCap Health Care ETF (PSCH), First Trust Active Factor Small Cap ETF (AFSM), ALPS Medical Breakthroughs ETF (SBIO) and SPDR S&P Biotech ETF (XBI).
What is Mihael H. Polymeropoulos' approval rating as Vanda Pharmaceuticals' CEO?: 12 employees have rated Vanda Pharmaceuticals Chief Executive Officer Mihael H. Polymeropoulos on Glassdoor.com. Mihael H. Polymeropoulos has an approval rating of 24% among the company's employees. This puts Mihael H. Polymeropoulos in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Vanda Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Vanda Pharmaceuticals investors own include FibroGen (FGEN), Zogenix (ZGNX), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Gilead Sciences (GILD), Exelixis (EXEL), Sangamo Therapeutics (SGMO), Array Technologies (ARRY), Micron Technology (MU) and Novavax (NVAX).

What is Vanda Pharmaceuticals' stock symbol?: Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."
Who are Vanda Pharmaceuticals' major shareholders?: Vanda Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (17.58%), State Street Corp (7.92%), Renaissance Technologies LLC (5.11%), Dimensional Fund Advisors LP (4.85%), Bank of America Corp DE (2.84%) and Pictet Asset Management SA (2.12%). Insiders that own company stock include Aranthan Jones II, Gunther Birznieks, Joakim Wijkstrom, Kevin Patrick Moran, Melissa Young, Mihael Hristos Polymeropoulos, Phaedra Chrousos, Richard W Dugan, Stephen Ray Mitchell, Thomas Watkins and Timothy Williams.
View institutional ownership trends.
How do I buy shares of Vanda Pharmaceuticals?: Shares of VNDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Vanda Pharmaceuticals' stock price today?: One share of VNDA stock can currently be purchased for approximately $6.06.
How much money does Vanda Pharmaceuticals make?: Vanda Pharmaceuticals (NASDAQ:VNDA) has a market capitalization of $348.09 million and generates $254.38 million in revenue each year. The biopharmaceutical company earns $6.28 million in net income (profit) each year or $0.29 on an earnings per share basis.
How many employees does Vanda Pharmaceuticals have?: The company employs 278 workers across the globe.
How can I contact Vanda Pharmaceuticals?: Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVENUE NW SUITE 300 E, WASHINGTON DC, 20037. The official website for the company is www.vandapharma.com. The biopharmaceutical company can be reached via phone at (202) 734-3400, via email at pr@vandapharma.com, or via fax at 202-296-1450.

This page (NASDAQ:VNDA) was last updated on 6/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial